Monoclonal antibodies (MABs) are a revolutionary advancement in cancer treatment. These targeted therapies are reshaping the way oncologists approach cancer care by offering a more
Columbia, Maryland – Dr. Ginette Serrero, CEO of A&G Pharmaceutical Inc., DBA Precision Antibody, will present two posters at the American Association of Cancer Research’s
Precision Antibody has an exclusive license agreement with trans-chromosomic (Tc) mice carrying mini-chromosomes with megabase-sized human immunoglobulin (Ig) loci. Precision Antibody has developed a proprietary
Precision Antibody contributes to the development of novel antibody reagents for the RAS signaling network The National Cancer Institute (NCI)’s RAS initiative has been working
COLUMBIA, Maryland, February 10, 2021: Precision Antibody and A&G Pharmaceutical are pleased to announce the publication, in PLOS One, of the results of their collaborative study
COLUMBIA, Maryland, September 7, 2020: A&G Pharmaceutical Inc., and its Custom Antibody Division Precision Antibody’s Progranulin ELISA kit used to investigate the correlation between progranulin serum
COLUMBIA, Maryland, September 7, 2020: A&G Pharmaceutical Inc., and its Custom Antibody Division Precision Antibody’s Progranulin ELISA kit used to investigate the correlation between progranulin
COLUMBIA, Maryland, August 31, 2020: A&G Pharmaceutical, Inc (A&G), with its Custom Antibody Division Precision Antibody has developed mouse monoclonal antibodies (mAbs) against COVID-19 antigens;
Precision Antibody™ is the forefront of the global Custom Antibody industry & it is led by the innovative minds in immunology and antibody development field.
